Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Stock Forecast

Stock Price Forecast

The 21 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $779, which forecasts a 20.93% increase in the stock price over the next year. The lowest target is $584 and the highest is $1,150.

Price Target: $779 (+20.93%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$584	$779	$781	$1,150
Change	-9.34%	+20.93%	+21.24%	+78.52%

Analyst Ratings

The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	May '25	Jun '25	Jul '25	Aug '25	Sep '25	Oct '25
Strong Buy	7	7	6	6	6	6
Buy	11	11	11	10	10	9
Hold	5	5	5	6	6	5
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	24	24	23	23	23	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Geoff Meacham Citigroup	Citigroup	Strong Buy Maintains $660 → $700	Strong Buy	Maintains	$660 → $700	+8.66%	Oct 29, 2025
Brian Abrahams RBC Capital	RBC Capital	Hold Maintains $704 → $708	Hold	Maintains	$704 → $708	+9.91%	Oct 29, 2025
Mohit Bansal Wells Fargo	Wells Fargo	Hold Maintains $580 → $615	Hold	Maintains	$580 → $615	-4.53%	Oct 29, 2025
Carter Gould Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $678 → $740	Buy	Maintains	$678 → $740	+14.87%	Oct 29, 2025
Yatin Suneja Guggenheim	Guggenheim	Strong Buy Maintains $815 → $865	Strong Buy	Maintains	$815 → $865	+34.28%	Oct 29, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

14.39B

Increased by 1.34%

from 14.20B

Revenue Next Year

15.15B

Increased by 5.23%

from 14.39B

EPS This Year

42.76

Increased by 11.52%

from 38.34

EPS Next Year

44.42

Increased by 3.89%

from 42.76

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	8.50B	16.07B	12.17B	13.12B	14.20B	14.39B	15.15B
Revenue Growth	29.58%	89.14%	-24.26%	7.76%	8.27%	1.34%	5.23%
EPS	30.52	71.97	38.22	34.77	38.34	42.76	44.42
EPS Growth	65.33%	135.81%	-46.90%	-9.03%	10.27%	11.52%	3.89%
Forward PE	-	-	-	-	-	15.07	14.50
No. Analysts	-	-	-	-	-	30	28

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	15.3B	17.1B
Avg	14.4B	15.1B
Low	13.1B	13.1B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	7.7%	18.7%
Avg	1.3%	5.2%
Low	-7.9%	-9.2%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	48.14	53.36
Avg	42.76	44.42
Low	33.63	36.10

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	25.6%	24.8%
Avg	11.5%	3.9%
Low	-12.3%	-15.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.